Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (541-550 of 591) with videos related to

Pageof 60
Sort By:
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
The New England Journal of Medicine|October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerStephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Cancer|February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panelRana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 StudyEvan Y Yu, William R Berry, Howard Gurney, et al.
Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Pageof 60

Showing results (541-550 of 591) with videos related to

Sort By:
Pageof 60
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
The New England Journal of Medicine|October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerStephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Cancer|February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panelRana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 StudyEvan Y Yu, William R Berry, Howard Gurney, et al.
Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Pageof 60